In China, the average value of enterprise value to earnings before interest, tax, depreciation and amortization (EV/EBITDA) in the health and pharmaceuticals sector as of 2023 was a multiple of approximately 22.1x. Companies operating in the hospitals and healthcare facilities industry saw the highest valuation multiple with EV/EBITDA valued at 38x.
Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2023, by industry
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic EV/EBITDA in the health and pharmaceuticals sector in emerging markets 2019-2023
- Premium Statistic EV/EBITDA in the health and pharmaceuticals sector in the U.S. 2019-2023, by industry
- Premium Statistic ROE in the health & pharmaceuticals sector in Europe 2019-2023, by industry
- Premium Statistic EV/EBITDA in the construction sector in the U.S. 2019-2023, by industry
- Premium Statistic EV/EBITDA in the chemicals and resources sector in Europe 2019-2023, by industry
- Premium Statistic EV/EBITDA in the metals and electronics sector in the U.S. 2019-2023, by industry
- Premium Statistic EV/EBITDA in energy & environmental services in China 2019-2023, by industry
- Premium Statistic EV/EBITDA in the consumer goods & FMCG sector in the U.S. 2019-2023, by industry
- Premium Statistic EV/EBITDA in media and advertising in emerging markets 2019-2023, by industry
- Premium Statistic EV/EBITDA in the construction sector in Europe 2019-2024, by industry
About the region
10
- Premium Statistic EV/EBITDA in the retail and trade sector in China 2019-2023, by industry
- Premium Statistic EV/EBITDA in the metals and electronics sector in China 2019-2023, by industry
- Premium Statistic EV/EBITDA in the technology and telecommunications sector in China 2019-2023
- Premium Statistic EV/EBITDA in the transportation and logistics sector in China 2019-2023, by industry
- Premium Statistic EV/EBITDA in the chemicals and resources sector in the China 2019-2023, by industry
- Premium Statistic EV/EBITDA in the construction sector in China 2019-2023, by industry
- Premium Statistic EV/EBITDA in the consumer goods & FMCG sector in China 219-2023, by industry
- Premium Statistic EV/EBITDA in the finance, insurance and real estate sector in China 2019-2023
- Premium Statistic EV/EBITDA in the media and advertising sector in China 2019-2023, by industry
- Premium Statistic Transaction value of foreign company takeovers by Chinese companies 2022
Other regions
10
- Premium Statistic EV/EBITDA in the retail & trade sector worldwide 2019-2023, by industry
- Premium Statistic EV/EBITDA in the transportation & logistics sector in Europe 2019-2023, by industry
- Premium Statistic EV/EBITDA in transportation and logistics in the U.S. 2019-2023, by industry
- Premium Statistic Number of M&A deals in Italy H1 2021, by sector
- Premium Statistic Outbound M&A deal value in the medical device sector in Hong Kong 2016-2019
- Basic Statistic COVID-19: Industries negatively affected according to PE investors DACH region 2020
- Premium Statistic Value of private equity deals in Romania 2017-2019
- Premium Statistic Media and entertainment average value/EBITDA Worldwide 2010-2018, by region
- Basic Statistic Number of M&A transactions in Asia 2015-2017, by country
- Premium Statistic M&A activity in Russia: aggregate value of transactions 2011-2021
Related statistics
10
- Premium Statistic EV/EBITDA in energy & environmental services worldwide 2019-2023, by industry
- Premium Statistic EV/EBITDA in the chemicals and resources sector in the U.S. 2019-2023, by industry
- Premium Statistic EV/EBITDA in the consumer goods & FMCG sector worldwide 2019-2023, by industry
- Premium Statistic EV/EBITDA in the transportation & logistics sector worldwide 2023, by industry
- Premium Statistic EV/EBITDA in the technology and telecommunications sector in the U.S. 2019-2023
- Premium Statistic EV/EBITDA in the energy & environmental services sector in the U.S. 2023, by industry
- Premium Statistic EV/EBITDA in the construction sector worldwide 2019-2023, by industry
- Premium Statistic EV/EBITDA in the technology & telecommunications sector worldwide 2023, by industry
- Premium Statistic EV/EBITDA in the consumer goods & FMCG sector in Europe 2019-2023, by industry
- Premium Statistic EV/EBITDA in the chemicals and resources sector worldwide 2019-2023, by industry
Further related statistics
10
- Financial advisors ranked by M&A transactions in the UK 2022, by deal value
- Hugo Boss - EBITDA 2005-2023
- Net earnings of UnitedHealth Group 2007-2023
- Leading financial advisors to M&A deals in the UK 2022, by deal volume
- Overweight prevalence in England 2000-2021, by gender
- Medicaid long-term care services expenditures by type of service 1990-21
- Rate of new cases of tuberculosis in the U.S. 1960-2019
- New cases of Lyme disease in the U.S. 1991-2019
- Deaths by motor vehicle-related injuries in the U.S. 1930-2022
- Deaths by prostate cancer in the U.S. 1950-2019
Further Content: You might find this interesting as well
Statistics
- Financial advisors ranked by M&A transactions in the UK 2022, by deal value
- Hugo Boss - EBITDA 2005-2023
- Net earnings of UnitedHealth Group 2007-2023
- Leading financial advisors to M&A deals in the UK 2022, by deal volume
- Overweight prevalence in England 2000-2021, by gender
- Medicaid long-term care services expenditures by type of service 1990-21
- Rate of new cases of tuberculosis in the U.S. 1960-2019
- New cases of Lyme disease in the U.S. 1991-2019
- Deaths by motor vehicle-related injuries in the U.S. 1930-2022
- Deaths by prostate cancer in the U.S. 1950-2019
Topics
Health careLeonard N. Stern School of Business. (January 5, 2023). Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2023, by industry [Graph]. In Statista. Retrieved May 23, 2024, from https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/
Leonard N. Stern School of Business. "Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2023, by industry." Chart. January 5, 2023. Statista. Accessed May 23, 2024. https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/
Leonard N. Stern School of Business. (2023). Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2023, by industry. Statista. Statista Inc.. Accessed: May 23, 2024. https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/
Leonard N. Stern School of Business. "Average Ev/Ebitda Multiples in The Health and Pharmaceuticals Sector in China from 2019 to 2023, by Industry." Statista, Statista Inc., 5 Jan 2023, https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/
Leonard N. Stern School of Business, Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2023, by industry Statista, https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/ (last visited May 23, 2024)
Average EV/EBITDA multiples in the health and pharmaceuticals sector in China from 2019 to 2023, by industry [Graph], Leonard N. Stern School of Business, January 5, 2023. [Online]. Available: https://www.statista.com/statistics/1030195/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-in-china/